Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Entrada Therapeutics Inc (TRDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TRDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.5
1 Year Target Price $20.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.85% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 262.26M USD | Price to earnings Ratio 11.91 | 1Y Target Price 20.5 |
Price to earnings Ratio 11.91 | 1Y Target Price 20.5 | ||
Volume (30-day avg) 4 | Beta -0.06 | 52 Weeks Range 6.70 - 21.79 | Updated Date 06/29/2025 |
52 Weeks Range 6.70 - 21.79 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-13 | When Before Market | Estimate -0.775 | Actual -0.42 |
Profitability
Profit Margin 14.39% | Operating Margin (TTM) -105.99% |
Management Effectiveness
Return on Assets (TTM) 0.51% | Return on Equity (TTM) 7.22% |
Valuation
Trailing PE 11.91 | Forward PE 3333.33 | Enterprise Value -63259889 | Price to Sales(TTM) 1.52 |
Enterprise Value -63259889 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA 1.58 | Shares Outstanding 37953400 | Shares Floating 18649706 |
Shares Outstanding 37953400 | Shares Floating 18649706 | ||
Percent Insiders 12.39 | Percent Institutions 80.1 |
Analyst Ratings
Rating 2 | Target Price 20.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Entrada Therapeutics Inc
Company Overview
History and Background
Entrada Therapeutics Inc. is a biopharmaceutical company founded in 2016. It focuses on developing intracellularly-acting therapeutics to treat diseases. The company's proprietary Endosomal Escape Vehicle (EEVu2122) platform aims to deliver a wide range of therapeutics into cells.
Core Business Areas
- EEV Therapeutics Development: Developing novel therapeutics for diseases that have been traditionally difficult to address due to intracellular targets. The EEV platform delivers these therapeutics inside the cell.
Leadership and Structure
The company's leadership team includes Dipal Doshi, CEO and President, and other executives with expertise in drug development and biotechnology. Entrada operates with a research and development-focused structure.
Top Products and Market Share
Key Offerings
- ENTR-601 (Duchenne Muscular Dystrophy): ENTR-601 is an investigational phosphorodiamidate morpholino oligomer (PMO) designed to treat Duchenne muscular dystrophy (DMD) by skipping exon 44. While specific market share data is unavailable due to its investigational status, competitors in DMD exon-skipping therapies include Sarepta Therapeutics (SRP). Revenue from this product is currently $0 as it is still in trials.
- Other EEV-based pipeline candidates: Entrada is developing a pipeline of EEV-based therapeutics for various diseases, including neuromuscular, immunology, and oncology indications. Market share and revenue data are not yet available for these pipeline candidates. Competitors vary depending on the target indication.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, high regulatory hurdles, and significant investment. There is a high need for novel drug delivery systems to address diseases at the cellular level. Gene therapies and targeted therapies are also important trends.
Positioning
Entrada Therapeutics is positioned as an innovator in intracellular drug delivery using its EEV platform. Its competitive advantage lies in its proprietary technology's ability to deliver a wide range of therapeutic modalities into cells, potentially addressing previously undruggable targets.
Total Addressable Market (TAM)
The total addressable market for therapies targeting intracellular diseases is substantial and growing. While a precise TAM figure is unavailable, it encompasses numerous diseases including DMD, autoimmune disorders, and certain cancers. Entrada is positioned to capture a portion of this TAM through its EEV platform and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Proprietary EEV platform for intracellular drug delivery
- Strong intellectual property portfolio
- Pipeline of novel therapeutic candidates
- Experienced management team
Weaknesses
- Reliance on novel technology with inherent risks
- Limited clinical data for key programs
- High cash burn rate associated with drug development
- Dependence on partnerships for development and commercialization
Opportunities
- Expanding the EEV platform to new therapeutic areas
- Securing partnerships with larger pharmaceutical companies
- Advancing pipeline candidates through clinical development
- Addressing unmet medical needs with novel therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Funding constraints
Competitors and Market Share
Key Competitors
- SRP
Competitive Landscape
Entrada's competitive advantage lies in its EEV platform's ability to deliver a wide range of therapeutics into cells. However, it faces competition from established pharmaceutical companies with greater resources and experience in drug development. Sarepta Therapeutics (SRP) has a substantial lead in approved DMD exon-skipping therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of the EEV platform and the expansion of its pipeline. The company's growth is tied to successful clinical trials and partnerships.
Future Projections: Future growth projections are based on analyst estimates and the company's own forecasts. Successful clinical development of ENTR-601 and other pipeline candidates is crucial for future growth.
Recent Initiatives: Recent initiatives include advancing ENTR-601 into clinical trials, expanding the EEV platform to new therapeutic areas, and forming partnerships to accelerate drug development.
Summary
Entrada Therapeutics is a promising biopharmaceutical company with a novel drug delivery platform. The success of their pipeline candidates is critical for long-term growth. Entrada needs to manage its cash burn and secure partnerships to advance its programs. Clinical trial results and regulatory approvals will heavily impact the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Entrada Therapeutics Inc. website
- SEC Filings (10-K, 10-Q)
- Analyst reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entrada Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | CEO & Director Mr. Dipal Doshi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.entradatx.com |
Full time employees 183 | Website https://www.entradatx.com | ||
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.